Chronic myelogenous leukemia (CML) is a malignant myeloid disorder characterized by the presence of a distinctive cytogenetic abnormality known as the Philadelphia chromosome.

Exposure to ionizing radiation is the only known risk factor with median presentation at age >50 years old.

Three phases of the disorder are chronic, accelerated and blast.

Choice of therapy is influenced by age, availability of a donor, comorbidities and phase of CML.

  1. American Cancer Society. What is chronic myeloid leukemia. American Cancer Society website. Feb 2016.
  2. Assouline S, Lipton JH. Monitoring response and resistance to treatment in chronic myeloid leukemia. Current Oncol. 2011 Apr;18(2):e71-e83. PMID: 21505592
  3. Baccarani M, Castagnetti F, Gugliotta G. Treatment recommendations for chronic myeloid leukemia. Mediterr J Hematol Infect Disease. 2014 Jan;6(1):e2014005. doi: 10.4084/MJHID.2014.005.
  4. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet Recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013 Aug;122(6):872-884. doi: 10.1182/blood-2013-05-501569. PMID: 23803709
  5. Baccarani M, Pileri S, Steegmann JL, et al. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2012 Oct;23(Suppl 7):vii72-vii77. doi:10.1093/annonc/mds228. PMID: 22997458
  6. Cancer Research UK. Types of treatment for chronic myeloid leukemia. Cancer Research UK website. Nov 2014.
  7. Cross NC, White HE, Colomer D. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015 May;29(5):999-1003. doi: 10.1038/leu.2015.29. PMID: 25652737
  8. Deeg HJ, Sandmaier BM. Determining eligibility for hematopoietic cell transplantation. UptoDate website. Mar 2016.
  9. Hirji I, Gupta S, Goren A, et al. Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient’s perspective. Health Qual Life Outcomes. 2013 Oct;11:167. doi: 10.1186/1477-7525-11-167. PMID: 24099272
  10. National Cancer Institute. General information about chronic myelogenous leukemia (CML). National Cancer Institute website. Mar 2016.
  11. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia version 1.2016. NCCN website. Sep 09, 2015.
  12. Negrin RS. Hematopoietic cell transplantation in chronic myeloid leukemia. UptoDate website. Apr 2016.
  13. Negrin RS, Schiffer CA. Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia. UptoDate website. Feb 2016.
  14. Negrin RS, Schiffer CA. Overview of the treatment of chronic myeloid leukemia. UptoDate website. treatment+of+chronic+myeloid+leukemia&selected Title=1%7E150. Feb 2016.
  15. Negrin RS, Schiffer CA. Treatment of chronic myeloid leukemia in accelerated phase. UptoDate website. of+chronic+myeloid+leukemia+in+accelerated +phase&selectedTitle=1%7E150. July 2015.
  16. Negrin RS, Schiffer CA. Treatment of myeloid leukemia in blast crisis. UptoDate website. http://www.uptodatecom/contents/treatment-of-chronic-myeloid-leukemia-in-blast-crisis? source=search_result&search=Treatment+of+chronic+ myeloid+leukemia+in+blast+crisis&selectedTitle=1~150. Sep 2014.
  17. Negrin RS, Schiffer CA. Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy. UptoDate website.§ionName=Omacetaxine&anchor=H24874435#H24874435. Apr 2016.
  18. Oehler VG. Update on current monitoring recommendations in chronic myeloid leukemia: practical points for clinical practice. Hematology Am Soc Hematol Educ Program. 2013;2013:176-183. doi: 10.1182/asheducation-2013.1.176. PMID: 24319179
  19. Rytting ME. Chronic myelogenous leukemia. MSD Manual. Oct 2014.
  20. Rochau U, Kluibenschaedl M, Stenehjem D, et al. Effectiveness and cost-effectiveness of sequential treatment of patients with chronic myeloid leukemia in the United States: a decision analysis. Leuk Res Treatment. 2015;2015:982395. doi: 10.1155/2015/982395. PMID: 26783469
  21. Van Etten RA. Cellular and molecular biology of chronic myeloid leukemia. UptoDate website. ?source=search_result&search=Cellular+and+molecular +biology+of+chronic+myeloid+leukemia& selectedTitle=1~150. Apr 2016.
  22. Van Etten RA. Clinical manifestations and diagnosis of chronic myeloid leukemia. UptoDate website. -and-diagnosis-of-chronic-myeloid-leukemia?source=search_result&search=clinical+manifestations+and+diagnosis+ of+chronic+myeloid+leukemia&selectedTitle=1~150. Apr 2016.
  23. Van Etten RA. Molecular genetics of chronic myeloid leukemia. UptoDate website. molecular-genetics-of-chronic-myeloid-leukemia? source=search_result&search=Quantitative+ RT-PCR+%28QPCR%29&selectedTitle=5~150. Sep 2015.
  24. Waclaw J, Sacha T, Soklosa T. Imatinib in the treatment of chronic myeloid leukemia: Current perspectives on optimal dose. Cancer Therapy Advisor. optimal-dosage/article/438571/. Sep 2015.
  25. World Health Organization. Chronic myelogenous leukemia. World Health Organization website. /applications/CML.pdf?ua=1. 2014.
  26. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology (NCCN Guidelines): chronic myeloid leukemia. Version 1.2017. NCCN website. 15 Nov 2016.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr. Joseph Delano Fule Robles, 06 May 2019

Gilteritinib, a novel inhibitor of the tyrosine kinase FLT3, improves survival outcomes among patients with relapsed or refractory acute myeloid leukaemia (AML) with FLT3 mutations vs standard chemotherapy, according to results of the phase III ADMIRAL trial reported at the American Association for Cancer Research (AACR) Annual Meeting 2019 held in Atlanta, Georgia, US.

Roshini Claire Anthony, 30 Apr 2019

Patients with advanced small cell lung cancer (SCLC) who experience disease progression despite two or more lines of therapy could benefit from pembrolizumab in the third-line setting, according to results from the phase 1b KEYNOTE-028 and phase II KEYNOTE-158* studies presented at AACR 2019.